TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8105678

Group type: COMPARATOR
Intervention: 3-day treatment with amoxicillin and clavulanate potassium (20 mg/kg per day of amoxicillin and 5 mg/kg per day of clavulanate potassium in three divided doses)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 10-day treatment with amoxicillin and clavulanate potassium (20 mg/kg per day of amoxicillin and 5 mg/kg per day of clavulanate potassium in three divided doses)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Infections involving adhesin-negative isolates
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Infections involving adhesin-positive isolates
Number of subjects: 37
Study: 3690939

Group type: EXPERIMENTAL
Intervention: Digoxin, 1.0 mg intravenously
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo intravenously
Number of subjects: 8
Study: 31167551

Group type: EXPERIMENTAL
Intervention: psychosexual intervention
Number of subjects: 46
Study: 29683921

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 54

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 54
Study: 28686823

Group type: EXPERIMENTAL
Intervention: Imaginal exposure plus methylene blue (IE + MB)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Imaginal exposure plus placebo (IE + PBO)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Waitlist (WL/standard PE)
Number of subjects: 42
Study: 25705798

Group type: EXPERIMENTAL
Intervention: 20 mg yohimbine HCl
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 52
Study: 23199095

Group type: EXPERIMENTAL
Intervention: RMT
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: PMT
Number of subjects: 39

Group type: COMPARATOR
Intervention: C
Number of subjects: 39
Study: 21036510

Group type: EXPERIMENTAL
Intervention: Outreach case management (OCM)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Passive referral
Number of subjects: 230
Study: 18496183

Group type: EXPERIMENTAL
Intervention: rFVIIa (40, 80, 120, 160, and 200 microg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rFVIIa (combined treatment group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rFVIIa (80-200 microg/kg)
Number of subjects: 0
Study: 16541277

Group type: EXPERIMENTAL
Intervention: Low-fat, high-fibre diet
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: High-fat, low-fibre diet
Number of subjects: 500

Group type: COMPARATOR
Intervention: Low-fat/high-fibre diet
Number of subjects: 500
Study: 14712893

Group type: EXPERIMENTAL
Intervention: Antiplatelet agents (specific agents not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of antiplatelet agents (specific agents not mentioned)
Number of subjects: 0
Study: 10925615

Group type: EXPERIMENTAL
Intervention: Single radiation dose of 8 Gy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ten treatments of 3 Gy delivered over two weeks
Number of subjects: 0
Study: 8922218

Group type: EXPERIMENTAL
Intervention: Fluid infusion pump pressures maintained below women's mean arterial pressures (MAPs)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fluid infusion pump pressures set at random
Number of subjects: 40
Study: 1565267

Group type: EXPERIMENTAL
Intervention: Thymopentin (50 mg) given three times before surgery and three times after surgery
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group (no thymopentin)
Number of subjects: 138
Study: 30064582

Group type: EXPERIMENTAL
Intervention: SIGNOUT? method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 9Ds method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no method used)
Number of subjects: 0
Study: 26620092

Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 203

Group type: COMPARATOR
Intervention: General practitioner (GP) care
Number of subjects: 203
Study: 25059308

Group type: EXPERIMENTAL
Intervention: MPR-R (MPR plus lenalidomide maintenance)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MP (melphalan and prednisone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MPR (MP plus lenalidomide)
Number of subjects: 0
Study: 22626675

Group type: EXPERIMENTAL
Intervention: 3.75 μg of antigen with half the standard dose of MF59 adjuvant
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: 7.5 μg of antigen with a full dose of MF59 adjuvant
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Non-adjuvanted vaccine containing 15 μg of antigen
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: 3.75 μg adjuvanted formulation
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: 7.5 μg adjuvanted formulation
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Booster vaccination with seasonal influenza vaccine
Number of subjects: 812
Study: 20385711

Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg bid
Number of subjects: 1258

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1258

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 1258
Study: 18166097

Group type: EXPERIMENTAL
Intervention: Periodontal therapy (scaling and root planing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Community dental care (control)
Number of subjects: 0
Study: 17149989

Group type: EXPERIMENTAL
Intervention: Caffeine supplementation (201 mg of caffeine per day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (3 pills per day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Caffeine supplementation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 14976565

Group type: EXPERIMENTAL
Intervention: RAC4 (rabeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 4 days)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: RAC7 (rabeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days)
Number of subjects: 70

Group type: COMPARATOR
Intervention: OAC7 (omeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days)
Number of subjects: 70
Study: 10601778

Group type: EXPERIMENTAL
Intervention: Fibre‐optic transillumination (FOTI)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Elective temporary tooth separation (ETTS)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Electronic caries measurement (ECM)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Clinical visual examination at the D(1) threshold
Number of subjects: 182
Study: 8785151

Group type: EXPERIMENTAL
Intervention: Deflation of the LMA cuff to a pressure of 22 mm Hg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Complete cuff deflation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Undisturbed LMA cuff
Number of subjects: 56
Study: 1329159

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bromazepam 6 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bromazepam 12 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 60
Study: 2931968

Group type: EXPERIMENTAL
Intervention: Fluosol‐DA 20% (FL)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Lactated Ringer's solution (LR)
Number of subjects: 34
Study: 30790440

Group type: EXPERIMENTAL
Intervention: Eccentric exercise programme with vibration training
Number of subjects: 61

Group type: COMPARATOR
Intervention: Eccentric exercise programme combined with cryotherapy
Number of subjects: 61
Study: 29059600

Group type: EXPERIMENTAL
Intervention: 17alpha‐methyltestosterone (MT) at 15.0 mg/kg (T3)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 17alpha‐methyltestosterone (MT) at 30.0 mg/kg (T4)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 17alpha‐methyltestosterone (MT) at 0.3 mg/kg (T1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 17alpha‐methyltestosterone (MT) at 3.0 mg/kg (T2)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no hormone)
Number of subjects: 100
Study: 26574050

Group type: EXPERIMENTAL
Intervention: Exercise intervention (60 minutes general fitness class, 40 minutes endurance training/aerobic, 20 minutes strength training and stretching/relaxation, performed at least twice per week for a minimum of 12 weeks)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Exercise intervention (≥ 24 sessions)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Exercise group (≥ 19 sessions, n=21 or ≥ 24 sessions, n=14)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 105
Study: 24693953

Group type: EXPERIMENTAL
Intervention: Echocardiographic optimization of AV and VV delay
Number of subjects: 400

Group type: COMPARATOR
Intervention: Haemodynamic optimization using non‐invasive blood pressure monitoring
Number of subjects: 400
Study: 22358123

Group type: EXPERIMENTAL
Intervention: ramosetron 0.3 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: dexamethasone 8 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ramosetron 0.3 mg combined with dexamethasone 8 mg
Number of subjects: 120
Study: 20053272

Group type: EXPERIMENTAL
Intervention: Pilot studies for phase III trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pilot studies
Number of subjects: 0
Study: 19037777

Group type: EXPERIMENTAL
Intervention: Automated proprioception assessment using a magnetic motion tracking system
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (neurologically intact subjects)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Automated proprioception assessment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 15983182

Group type: EXPERIMENTAL
Intervention: Isometric-only resistance training
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isokinetic concentric-only resistance training
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isokinetic eccentric-only resistance training
Number of subjects: 30
Study: 12463731

Group type: EXPERIMENTAL
Intervention: Nateglinide (120 mg, 10 min before meals for 4 days) + Warfarin (30 mg on the second day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Warfarin (30 mg) alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nateglinide + Warfarin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Warfarin alone
Number of subjects: 12
Study: 10513507

Group type: EXPERIMENTAL
Intervention: Ibuprofen 2,400 mg/day for 28 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SF‐36
Number of subjects: 0
Study: 7695978

Group type: EXPERIMENTAL
Intervention: GM-CSF (5 micrograms/kg/day subcutaneously, days 5 to > 18)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: GM-CSF (5 micrograms/kg/day subcutaneously, days 12 to > 18)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Carboplatin (400 mg/m2 intravenous day 1) and Etoposide (100 mg/m2 intravenous days 1 to > 3)
Number of subjects: 13
Study: 1710750

Group type: EXPERIMENTAL
Intervention: Alfuzosin (daily dose 7.5‐10 mg)
Number of subjects: 518
Study: 7464561

Group type: EXPERIMENTAL
Intervention: Colestipol (30 g/day)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Clofibrate
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Clofibrate (in certain patients)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (Avicel powder)
Number of subjects: 27
Study: 31923136

Group type: EXPERIMENTAL
Intervention: Single-stage open reduction and Pemberton periacetabular osteotomy (PPO)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Two separate consecutive operations
Number of subjects: 130
Study: 31567670

Group type: EXPERIMENTAL
Intervention: Operative approach algorithm
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Fixation technique algorithm
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Bearing surface algorithm
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: NLP algorithms applied to operative reports from other institutions
Number of subjects: 29
Study: 27855489

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) applied to vastus medialis and vastus lateralis muscles
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham taping across the same muscle groups
Number of subjects: 16

Group type: COMPARATOR
Intervention: No taping
Number of subjects: 16
Study: 25532912

Group type: EXPERIMENTAL
Intervention: Action Observation (AO)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Motor Imagery (MI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 30
Study: 24382002

Group type: EXPERIMENTAL
Intervention: Romosozumab 210 mg monthly
Number of subjects: 419

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 419

Group type: COMPARATOR
Intervention: Alendronate 70 mg weekly
Number of subjects: 419

Group type: COMPARATOR
Intervention: Teriparatide 20 μg daily
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Romosozumab (all doses)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Romosozumab
Number of subjects: 419
Study: 21881869

Group type: EXPERIMENTAL
Intervention: EMD + BCP
Number of subjects: 24

Group type: COMPARATOR
Intervention: EMD
Number of subjects: 24
Study: 20025373

Group type: EXPERIMENTAL
Intervention: Guided self‐change (GSC) treatment in group format
Number of subjects: 264

Group type: COMPARATOR
Intervention: Guided self‐change (GSC) treatment in individual format
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Group format
Number of subjects: 264
Study: 17434635

Group type: EXPERIMENTAL
Intervention: Oral Amiodarone (600 mg in three divided doses)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Intravenous Amiodarone (5 mg/kg over 30 min followed by 1000 mg over the next 24 h)
Number of subjects: 223
Study: 16275380

Group type: EXPERIMENTAL
Intervention: Prick-to-prick testing with fresh apples
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Golden Delicious and Santana cultivars tested with double-blind, placebo-controlled food challenge (DBPCFC)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Controlled atmosphere storage (2.5% oxygen/1% carbon dioxide)
Number of subjects: 29
Study: 11869844

Group type: EXPERIMENTAL
Intervention: Nesiritide (0.015 or 0.03 microg/kg per min)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 261
Study: 10587915

Group type: EXPERIMENTAL
Intervention: Verbal instructions and demonstration on breath actuated inhaler technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Written instructions only on BAI use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 0
Study: 7758236

Group type: EXPERIMENTAL
Intervention: Graves' disease patients
Number of subjects: 95

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 95
Study: 1713882

Group type: EXPERIMENTAL
Intervention: Dose-reduced induction therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard induction therapy
Number of subjects: 0
Study: 7377854

Group type: EXPERIMENTAL
Intervention: General practitioner care
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Attendance at hospital outpatient clinics
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Follow-up by a senior occupational therapist
Number of subjects: 132

Group type: COMPARATOR
Intervention: Overall care judged by an independent assessor
Number of subjects: 132
Study: 31547798

Group type: EXPERIMENTAL
Intervention: Open-cell stents
Number of subjects: 714

Group type: COMPARATOR
Intervention: Closed-cell stents
Number of subjects: 714
Study: 27696475

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 25960303

Group type: EXPERIMENTAL
Intervention: Exercise training (3-month home-based aerobic training program: 4 daily cycling sessions of 10 minutes each at 90% of heart rate at anaerobic threshold)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual care (standard therapy)
Number of subjects: 48
Study: 23361519

Group type: EXPERIMENTAL
Intervention: 20 mg MPH
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 21487873

Group type: EXPERIMENTAL
Intervention: Nonfixation of mesh
Number of subjects: 772
Study: 19920784

Group type: EXPERIMENTAL
Intervention: ivabradine 12.5 mg/day
Number of subjects: 30
Study: 17303706

Group type: EXPERIMENTAL
Intervention: Hvy-Ramp
Number of subjects: 8

Group type: COMPARATOR
Intervention: Mod-Ramp
Number of subjects: 8
Study: 15126749

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O) anesthesia
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no N2O)
Number of subjects: 27
Study: 11105740

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 284
Study: 9169252

Group type: EXPERIMENTAL
Intervention: Ocusert Pilo 40
Number of subjects: 3

Group type: COMPARATOR
Intervention: Intensive pilocarpine regimen
Number of subjects: 3

Group type: COMPARATOR
Intervention: Low-dose pilocarpine treatment
Number of subjects: 3
Study: 1505412

Group type: EXPERIMENTAL
Intervention: Participatory health education
Number of subjects: 200

Group type: COMPARATOR
Intervention: Passive control
Number of subjects: 200
Study: 6511134

Group type: EXPERIMENTAL
Intervention: Activated charcoal (2.5 g) administered immediately after the drugs
Number of subjects: 6

Group type: COMPARATOR
Intervention: Antacid (20 ml of 8.5% magnesium hydroxide)
Number of subjects: 6
Study: 30810400

Group type: EXPERIMENTAL
Intervention: Double trigger (GnRH agonist and hCG, 40 and 34 h prior to OPU)
Number of subjects: 33

Group type: COMPARATOR
Intervention: hCG trigger (36 h before OPU)
Number of subjects: 33

Group type: COMPARATOR
Intervention: GnRH agonist trigger (GnRHag 36 h before OPU and hCG on day of OPU)
Number of subjects: 33
Study: 29487991

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control
Number of subjects: 94
Study: 27338470

Group type: EXPERIMENTAL
Intervention: Underweight (<18.5 kg/m²)
Number of subjects: 20694

Group type: COMPARATOR
Intervention: Normal weight (18.5-23.9 kg/m²)
Number of subjects: 20694

Group type: EXPERIMENTAL
Intervention: Overweight (24.0-27.9 kg/m²)
Number of subjects: 20694

Group type: EXPERIMENTAL
Intervention: Obesity (≥28.0 kg/m²)
Number of subjects: 20694
Study: 26068513

Group type: EXPERIMENTAL
Intervention: Primary care physician contact within 1 month of follow-up
Number of subjects: 847
Study: 21859219

Group type: EXPERIMENTAL
Intervention: Therapeutic intervention for nonsuicidal self-harm
Number of subjects: 70

Group type: COMPARATOR
Intervention: Suicidal self-harm
Number of subjects: 70
Study: 20484173

Group type: EXPERIMENTAL
Intervention: Flavonol intake (highest quartile)
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Decrease in IL‐6 concentration during the trial
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Above median flavonol intake with equal or below median IL‐6 change after baseline
Number of subjects: 872
Study: 18779774

Group type: EXPERIMENTAL
Intervention: quetiapine XR 600 mg/day
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: quetiapine XR 300 mg/day
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: quetiapine XR 800 mg/day
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: quetiapine IR 300 mg/day
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: quetiapine IR 600 mg/day
Number of subjects: 532

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 532
Study: 15967972

Group type: EXPERIMENTAL
Intervention: Liposomal lidocaine 4% cream
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 14601012

Group type: EXPERIMENTAL
Intervention: New procedure for estimating treatment effects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional procedure for estimating treatment effects
Number of subjects: 0
Study: 10231040

Group type: EXPERIMENTAL
Intervention: 100 mg of aspirin daily
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study: 8915811

Group type: EXPERIMENTAL
Intervention: Topical anesthesia
Number of subjects: 45

Group type: COMPARATOR
Intervention: Peribulbar anesthesia
Number of subjects: 45
Study: 1681265

Group type: EXPERIMENTAL
Intervention: Edmonston‐Zagreb high‐titre (EZ‐HT) vaccine at 5 months
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Schwarz high‐titre (SW‐HT) vaccine at 5 months
Number of subjects: 1015

Group type: COMPARATOR
Intervention: Placebo followed by standard low‐titre Schwarz vaccine at 10 months (standard)
Number of subjects: 1015
Study: 366539

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Challenge food materials
Number of subjects: 9

Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 9
Study: 31761946

Group type: EXPERIMENTAL
Intervention: Salt supplementation (100 mmol NaCl/24h)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31097853

Group type: EXPERIMENTAL
Intervention: Bupivacaine (5 mL of 0.25%)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Ketamine (100 mg)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo (5 cc distilled water)
Number of subjects: 99
Study: 27981268

Group type: EXPERIMENTAL
Intervention: Colgate Total toothpaste (triclosan/copolymer/fluoride)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Colgate Herbal toothpaste (0.243% sodium fluoride)
Number of subjects: 50
Study: 26138521

Group type: EXPERIMENTAL
Intervention: Modified Limberg flap transposition
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lateral advancement flap transposition with Burow's triangle
Number of subjects: 100
Study: 24189212

Group type: EXPERIMENTAL
Intervention: Bilevel positive airway pressure ventilation (BV)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham ventilation
Number of subjects: 10
Study: 21576658

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg twice a day
Number of subjects: 18113

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg twice a day
Number of subjects: 18113

Group type: COMPARATOR
Intervention: Dabigatran
Number of subjects: 18113